{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:05:52Z","timestamp":1788797152635,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81920108006"],"award-info":[{"award-number":["81920108006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270218"],"award-info":[{"award-number":["82270218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20291"],"award-info":[{"award-number":["U22A20291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00277-023-05573-z","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T02:01:22Z","timestamp":1701741682000},"page":"1305-1315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)"],"prefix":"10.1007","volume":"103","author":[{"given":"Lihui","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengteng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaishuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-4614","authenticated-orcid":false,"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"5573_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"K SK","year":"2017","unstructured":"SK K, R V, RA K, VD M, S P, MV M et al (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046","journal-title":"Nat Rev Dis Primers"},{"issue":"10272","key":"5573_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. The Lancet 397(10272):410\u2013427","journal-title":"The Lancet"},{"issue":"3","key":"5573_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H et al (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93(3):431\u2013438","journal-title":"Haematologica"},{"issue":"4","key":"5573_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/cyto.b.20512","volume":"78","author":"B Paiva","year":"2010","unstructured":"Paiva B, Almeida J, P\u00e9rez-Andr\u00e9s M, Mateo G, L\u00f3pez A, Rasillo A et al (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 78(4):239\u2013252","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"5573_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B, Perez JJ, B\u00f6ttcher S, Wind H et al (2016) Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 90(1):61\u201372","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"5573_CR6","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013ee46","journal-title":"Lancet Oncol"},{"issue":"4","key":"5573_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/leu.2017.320","volume":"32","author":"P Arana","year":"2018","unstructured":"Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB et al (2018) Prognostic value of antigen expression in multiple myeloma: a PETHEMA\/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia 32(4):971\u2013978","journal-title":"Leukemia"},{"issue":"3","key":"5573_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3892\/ijo.2012.1545","volume":"41","author":"Y Kawano","year":"2012","unstructured":"Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y et al (2012) Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol 41(3):876\u2013884","journal-title":"Int J Oncol"},{"issue":"2","key":"5573_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1365-2141.2005.05849.x","volume":"132","author":"P Moreau","year":"2006","unstructured":"Moreau P, Robillard N, J\u00e9go G, Pellat C, Le Gouill S, Thoumi S et al (2006) Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 132(2):168\u2013170","journal-title":"Br J Haematol"},{"issue":"1","key":"5573_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1365-2141.2003.04260.x","volume":"121","author":"JE Guikema","year":"2003","unstructured":"Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R et al (2003) CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 121(1):36\u201343","journal-title":"Br J Haematol"},{"key":"5573_CR11","doi-asserted-by":"publisher","first-page":"108363","DOI":"10.1016\/j.clim.2020.108363","volume":"213","author":"B Chu","year":"2020","unstructured":"Chu B, Bao L, Wang Y, Lu M, Shi L, Gao S et al (2020) CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma. Clin Immunol 213:108363","journal-title":"Clin Immunol"},{"issue":"11","key":"5573_CR12","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.18632\/oncotarget.3319","volume":"6","author":"F Li","year":"2015","unstructured":"Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F et al (2015) Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget 6(11):9434\u20139444","journal-title":"Oncotarget"},{"issue":"6","key":"5573_CR13","first-page":"1521","volume":"4","author":"N Robillard","year":"1998","unstructured":"Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP et al (1998) CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 4(6):1521\u20131526","journal-title":"Clin Cancer Res"},{"issue":"11","key":"5573_CR14","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1182\/blood-2006-03-012542","volume":"109","author":"NJ Bahlis","year":"2007","unstructured":"Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA et al (2007) CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 109(11):5002\u20135010","journal-title":"Blood"},{"issue":"24","key":"5573_CR15","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1182\/blood-2013-10-530964","volume":"123","author":"ME Murray","year":"2014","unstructured":"Murray ME, Gavile CM, Nair JR, Koorella C, Carlson LM, Buac D et al (2014) CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood 123(24):3770\u20133779","journal-title":"Blood"},{"issue":"11","key":"5573_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/sj.bmt.1705857","volume":"40","author":"M Hundemer","year":"2007","unstructured":"Hundemer M, Klein U, Hose D, Raab MS, Cremer FW, Jauch A et al (2007) Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 40(11):1033\u20131037","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"5573_CR17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1046\/j.1365-2141.2002.03513.x","volume":"117","author":"N Sahara","year":"2002","unstructured":"Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K et al (2002) Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 117(4):882\u2013885","journal-title":"Br J Haematol"},{"key":"5573_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.leukres.2015.11.003","volume":"40","author":"Y Pan","year":"2016","unstructured":"Pan Y, Wang H, Tao Q, Zhang C, Yang D, Qin H et al (2016) Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Res 40:77\u201382","journal-title":"Leuk Res"},{"issue":"1","key":"5573_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/16078454.2021.2019365","volume":"27","author":"L Zhang","year":"2022","unstructured":"Zhang L, Huang Y, Lin Y, Zhang A, Zou R, Xu H et al (2022) Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis. Hematology 27(1):122\u2013131","journal-title":"Hematology"},{"issue":"8","key":"5573_CR20","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/leu.2012.42","volume":"26","author":"B Paiva","year":"2012","unstructured":"Paiva B, Guti\u00e9rrez NC, Chen X, V\u00eddriales MB, Montalb\u00e1n M, Rosi\u00f1ol L et al (2012) Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 26(8):1862\u20131869","journal-title":"Leukemia"},{"issue":"16","key":"5573_CR21","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","volume":"26","author":"G Mateo","year":"2008","unstructured":"Mateo G, Montalb\u00e1n MA, Vidriales MB, Lahuerta JJ, Mateos MV, Guti\u00e9rrez N et al (2008) Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 26(16):2737\u20132744","journal-title":"J Clin Oncol"},{"issue":"10","key":"5573_CR22","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-04-1489","volume":"11","author":"G Mateo","year":"2005","unstructured":"Mateo G, Castellanos M, Rasillo A, Guti\u00e9rrez NC, Montalb\u00e1n MA, Mart\u00edn ML et al (2005) Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 11(10):3661\u20133667","journal-title":"Clin Cancer Res"},{"issue":"15","key":"5573_CR23","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2015-08-665679","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I et al (2016) Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood 127(15):1896\u20131906","journal-title":"Blood"},{"issue":"1","key":"5573_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","volume":"137","author":"I Goicoechea","year":"2021","unstructured":"Goicoechea I, Puig N, Cedena MT, Burgos L, Cord\u00f3n L, Vidriales MB et al (2021) Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood 137(1):49\u201360","journal-title":"Blood"},{"key":"5573_CR25","doi-asserted-by":"crossref","unstructured":"Radzevi\u010dius M, Dirs\u0117 V, Klimien\u0117 I, Matuzevi\u010dien\u0117 R, Ku\u010dinskien\u0117 ZA, Pe\u010deli\u016bnas V (2022) Multiple myeloma immunophenotype related to chromosomal abnormalities used in risk assessment. Diagnostics (Basel) 12(9)","DOI":"10.3390\/diagnostics12092049"},{"issue":"3","key":"5573_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nri1572","volume":"5","author":"M Shapiro-Shelef","year":"2005","unstructured":"Shapiro-Shelef M, Calame K (2005) Regulation of plasma-cell development. Nat Rev Immunol 5(3):230\u2013242","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"5573_CR27","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","volume":"102","author":"N Robillard","year":"2003","unstructured":"Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102(3):1070\u20131071","journal-title":"Blood"},{"issue":"8","key":"5573_CR28","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/sj.leu.2403823","volume":"19","author":"S Kumar","year":"2005","unstructured":"Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE (2005) CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 19(8):1466\u20131470","journal-title":"Leukemia"},{"issue":"5","key":"5573_CR29","first-page":"547","volume":"89","author":"P Moreau","year":"2004","unstructured":"Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N et al (2004) Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 89(5):547\u2013551","journal-title":"Haematologica"},{"issue":"26","key":"5573_CR30","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863\u20132869","journal-title":"J Clin Oncol"},{"key":"5573_CR31","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A et al (2022) Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol Jco2102614","DOI":"10.1200\/JCO.21.02614"},{"issue":"5","key":"5573_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K (2022) High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J 12(5):83","journal-title":"Blood Cancer J"},{"key":"5573_CR33","doi-asserted-by":"crossref","unstructured":"Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA et al (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia","DOI":"10.1038\/s41375-022-01597-y"},{"issue":"4","key":"5573_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","volume":"19","author":"AK Dutta","year":"2022","unstructured":"Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM (2022) Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol 19(4):223\u2013236","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"5573_CR35","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","volume":"21","author":"G An","year":"2015","unstructured":"An G, Li Z, Tai YT, Acharya C, Li Q, Qin X et al (2015) The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res 21(9):2148\u20132156","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5573_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1182\/bloodadvances.2021004992","volume":"6","author":"Y Yan","year":"2022","unstructured":"Yan Y, Qin X, Liu J, Fan H, Yan W, Liu L et al (2022) Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH. Blood Adv 6(2):441\u2013451","journal-title":"Blood Adv"},{"issue":"1","key":"5573_CR37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41467-022-28266-z","volume":"13","author":"M Merz","year":"2022","unstructured":"Merz M, Merz AMA, Wang J, Wei L, Hu Q, Hutson N et al (2022) Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat Commun 13(1):807","journal-title":"Nat Commun"},{"issue":"1","key":"5573_CR38","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1038\/s41467-023-40584-4","volume":"14","author":"L John","year":"2023","unstructured":"John L, Poos AM, Brobeil A, Schinke C, Huhn S, Prokoph N et al (2023) Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nat Commun 14(1):5011","journal-title":"Nat Commun"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05573-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05573-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05573-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T10:06:51Z","timestamp":1710410811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05573-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["5573"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05573-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"12 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, and the study was conducted in accordance with the local ethics committee and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}